TrialCancer2015

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Maria E Cabanillas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.